PTC Therapeutics (PTCT) Scheduled to Post Earnings on Thursday

PTC Therapeutics (NASDAQ:PTCT - Get Free Report) will be releasing its earnings data after the market closes on Thursday, November 7th. Analysts expect PTC Therapeutics to post earnings of ($1.52) per share for the quarter. PTC Therapeutics has set its FY 2024 guidance at EPS.Individual interested in listening to the company's earnings conference call can do so using this link.

PTC Therapeutics (NASDAQ:PTCT - Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($1.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.00) by ($0.16). The business had revenue of $186.70 million during the quarter, compared to the consensus estimate of $192.12 million. On average, analysts expect PTC Therapeutics to post $-5 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

PTC Therapeutics Trading Down 0.5 %

Shares of PTC Therapeutics stock traded down $0.20 on Thursday, hitting $40.46. The stock had a trading volume of 217,248 shares, compared to its average volume of 850,168. The stock has a market cap of $3.11 billion, a price-to-earnings ratio of -6.31 and a beta of 0.65. PTC Therapeutics has a 52-week low of $17.53 and a 52-week high of $43.40. The company's 50 day moving average price is $36.45 and its 200 day moving average price is $34.25.

Analyst Ratings Changes

PTCT has been the subject of several research analyst reports. Raymond James initiated coverage on PTC Therapeutics in a report on Thursday, October 10th. They issued a "market perform" rating for the company. UBS Group began coverage on PTC Therapeutics in a report on Monday, August 26th. They set a "buy" rating and a $47.00 price objective for the company. Royal Bank of Canada increased their price target on shares of PTC Therapeutics from $32.00 to $34.00 and gave the company a "sector perform" rating in a research report on Friday, October 4th. Morgan Stanley raised their target price on shares of PTC Therapeutics from $32.00 to $45.00 and gave the stock an "equal weight" rating in a research report on Friday, October 11th. Finally, Robert W. Baird restated an "outperform" rating and issued a $44.00 price target on shares of PTC Therapeutics in a report on Tuesday, October 8th. Three investment analysts have rated the stock with a sell rating, five have issued a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus price target of $40.08.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.